Accès ouvert
2024
review
OpenAlex
Juan Luis Alcázar, Laura Peñate, Virgina Casanova, Virginia Engels et autres
es, it
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Montserrat León‐García, Brittany Humphries, Feng Xie, Derek L. Gravholt et autres
BACKGROUND: Venous thromboembolism (VTE) in pregnancy is a major cause of maternal morbidity and mortality, and the use of preventive low-molecular-weight heparin (LMWH) can be challenging. Clinical guidelines recommend eliciting pregnant individuals' preferences towards the use of daily injections of LMWH and …
es, us, ca
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Montserrat León‐García, Brittany Humphries, Derek Gravholt, Elizabeth H. Golembiewski et autres
Introduction Venous thromboembolism (VTE) is a major cause of maternal morbidity and mortality, and the use of preventive low-molecular-weight heparin (LMWH) can be challenging. Clinical guidelines recommend eliciting pregnant individuals’ preferences towards the use of LMWH and discussing the best option through …
es, us, ca
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Montserrat León‐García, Brittany Humphries, Feng Xie, Derek Gravholt et autres
es, ca, us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Virginia Engels, Margarita Medina, E. Antolín, Cristina Ros et autres
Background: Tubal patency testing constitutes an essential part of infertility work-up. Hysterosalpingo-foam-sonography (HyFoSy) is currently one of the best tests for assessing tubal patency. The objective of our study was to evaluate the post-procedure rate of spontaneous pregnancy among infertile women submitted …
es
(code pays fourni par la source)
Accès ouvert
2022
review
OpenAlex
Montserrat León‐García, Brittany Humphries, Andrea Maraboto, Montserrat Rabassa et autres
BACKGROUND: Venous thromboembolism (VTE) in pregnancy is an important cause of maternal morbidity and mortality. Low-molecular-weight heparin (LMWH) is the cornerstone of prophylaxis and treatment of thrombotic events during pregnancy. LMWH has fewer adverse effects than other anticoagulants, does not cross the …
es, us, ca
(code pays fourni par la source)
2011
article
OpenAlex
Joanna Doona, Irene Pelayo
2008
article
OpenAlex
Irene Pelayo, Javier Haya, Juan J. de la Cruz, Carlos Seco et autres
OBJECTIVE: To compare the efficacy and safety of adding ossein-hydroxyapatite compound (OHC) or calcium carbonate (CC) to raloxifene (RLX) therapy for controlling bone loss in postmenopausal women. DESIGN: : Ninety postmenopausal women were assigned to treatment with RLX plus OHC (group 1, …
es
(code pays fourni par la source)